The company said that in the second half of 2020, its core business, excluding COVID-19 clinical reagents and testing revenues, remained resilient despite lockdowns.
The company now expects organic revenues to grow 40 percent year over year in Q4, driven by its base business and sales related to the COVID-19 response.
The company said that its Diagnostics and Genomics segment posted 18 percent growth driven by sales of RNAscope RNA in situ hybridization detection products.
The firm said that its molecular diagnostics revenues grew almost fivefold year over year, based on strong global demand for its SARS-CoV-2 molecular assays.